{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-037318","form_type":"8-K","ticker":"DERM","cik":"0001867066","company_name":"Journey Medical Corp","filed_at":"2024-03-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.159658+00:00","generated_at":"2026-06-04T10:28:29.173710+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Journey Medical reports FY2023 revenue $79.2M (+7% YoY); net loss narrows to $3.9M from $29.6M","bullets":["Total revenues $79.2M vs $73.7M in 2022; growth driven by $19.0M Maruho licensing revenue.","Net product revenues fell 16% to $59.7M due to generic competition and Ximino discontinuation.","Net loss improved to $3.9M ($0.21 loss per share) from $29.6M ($1.69 loss per share) in 2022.","Adjusted EBITDA turned positive to $15.6M ($0.85 basic EPS) from negative $7.3M in 2022.","NDA for rosacea candidate DFD-29 accepted by FDA; PDUFA goal date set for November 4, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-037318","json":"https://secwatch.observer/filing/0001104659-24-037318.json","markdown":"https://secwatch.observer/filing/0001104659-24-037318.md","text":"https://secwatch.observer/filing/0001104659-24-037318.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1867066/000110465924037318/0001104659-24-037318-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1867066/000110465924037318/tm249442d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T10:28:29.173710+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9bfbefc8f041bb0fbcdfd2eacd66fad0232f804b","claim":"Journey Medical Corp reported the full year ended December 31, 2023 results: revenue $79.2 million, net income $(3.9) million, EPS $(0.21) per share basic and diluted.","evidence_excerpt":"EXHIBIT 99.1 Exhibit 99.1 Journey Medical Corporation Reports Full-Year 2023 Financial Results and Recent Corporate Highlights Company generated total revenues of $79.2 million for the full year ended December 31, 2023, a 7% increase from the $73.7 million reported in 2022 Achieved $15.6 million in operating cost savings in 2023, ahead of initial","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1867066/000110465924037318/0001104659-24-037318-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full year ended December 31, 2023"},{"label":"Revenue","value":"$79.2 million"},{"label":"Net income","value":"$(3.9) million"},{"label":"EPS","value":"$(0.21) per share basic and diluted"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}